NanoTemper Introduces New Executive Leadership Team to Advance Biophysical Innovation
Team combines expertise in drug discovery and bioprocessing to accelerate therapy development
The formation of the executive team marks a significant milestone as NanoTemper builds on its strong foundation of scientific excellence and customer-centered innovation to advance biophysical characterization solutions that simplify complex science and accelerate drug discovery.
The NanoTemper executive leadership team is led by Stefan Duhr, Co-Founder and Chief Executive Officer, and includes:
- Eva Lindskog – Chief Commercial Officer
- Steffen Schneider – Chief Financial Officer
- Jörg Stegert – Chief Human Resources Officer
- Werner Streicher – Chief Scientific Officer
- Martin Zech – Chief Technology Officer (joining April 2026)
- Andreas Söllner – Chief of Staff
Together, the expanded leadership team brings experience in drug discovery, bioprocessing, customer partnerships, and scaling organization growth. Known for executing with scientific rigor while embracing bold ideas and new ways of working, the team reflects NanoTemper’s commitment to innovation through collaboration. With backgrounds that span disciplines and industries, they share a common commitment to NanoTemper’s core values and the goal of advancing science to build a future where every disease can be treated.
“We’ve created something truly special at NanoTemper, with over 200 team members around the world dedicated to helping researchers discover better therapies faster,” said Stefan Duhr, co-founder & CEO of NanoTemper. “Bringing together this leadership team who combine scientific depth, technological imagination, and a genuine commitment to our customers is a key investment in NanoTemper’s future. This team reflects our belief that innovation happens when curious, humble, values-driven people build together, and I’m excited about the impact we will co-create with researchers around the world.”
As NanoTemper enters its next phase of growth, this team will guide the company toward new breakthroughs, applications, and opportunities in support of our team and scientists worldwide.
Other news from the department people
